The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development - A potential therapeutic target?

Expert Review of Gastroenterology and Hepatology

Volumn 10, Issue 2, 2016, Pages 229-242

  Dongiovanni, Paola ^a   Rametta, Raffaela ^a   Meroni, Marica ^a   Valenti, Luca ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

insulin receptor signaling; Insulin resistance; liver disease progression; metformin; nonalcoholic fatty liver disease; obesity; obethicholic acid; pioglitazone; steatohepatitis; type 2 diabetes

Indexed keywords

ALPHA TOCOPHEROL; HORMONE RECEPTOR; INSULIN SENSITIZING AGENT; METFORMIN; NOTCH RECEPTOR; PEGINTERFERON; PIOGLITAZONE; RIBAVIRIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN;

CLINICAL RESEARCH; COMORBIDITY; DISEASE ASSOCIATION; DRUG TARGETING; ENVIRONMENTAL FACTOR; FIBROGENESIS; GENETIC DISORDER; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOPHYSIOLOGY; REVIEW; ANIMAL; BLOOD; DRUG DEVELOPMENT; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; LIVER; METABOLISM; MOLECULARLY TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; SIGNAL TRANSDUCTION;

ADIPOSITY; ANIMALS; BLOOD GLUCOSE; DRUG DISCOVERY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIVER; MOLECULAR TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; SIGNAL TRANSDUCTION;

EID: 84956780310     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2016.1110018     Document Type: Review

References (111)

1. Papers of special note have been highlighted as
2. ∗ of interest
3. ∗ of considerable interest
4. Bugianesi E, Gastaldelli A, Vanni E., et al. Insulin resistance in non-diabetic patients with non-Alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005; 48: 634-642
5. ∗ Important paper which describe the interaction between IR and NAFLD
6. Browning JD, Szczepaniak LS, Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40: 1387-1395
7. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003; 124: 71-79
8. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346: 1221-1231
9. Grancini V, Trombetta M, Lunati ME., et al. Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-Associated diabetes: role of severity of liver disease. J Hepatol. 2015; 63(6):1484-1490
10. Silverman JF, OBrien KF, Long S., et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol. 1990; 85: 1349-1355
11. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. Jama. 2003; 289: 3000-3004
12. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010; 363: 1341-1350
13. Cassader M, Gambino R, Musso G., et al. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids. 2001; 36: 1117-1124
14. McPherson S, Hardy T, Henderson E., et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015; 62: 1148-1155
15. Singh S, Allen AM, Wang Z., et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-Analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015; 13: 643-54.e1-9; quiz e39-40
16. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001; 414: 799-806
17. Pacini G. The hyperbolic equilibrium between insulin sensitivity and secretion. Nutr Metab Cardiovasc Dis. 2006; 16 (Suppl 1): S22-7
18. Kotronen A, Vehkavaara S, Seppala-Lindroos A., et al. Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab. 2007; 293: E1709-15
19. Matsumoto M, Han S, Kitamura T., et al. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest. 2006; 116: 2464-2472
20. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002; 109: 1125-1131
21. Valenti L, Rametta R, Dongiovanni P., et al. Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes. 2008; 57: 1355-1362
22. Matsumoto M, Pocai A, Rossetti L., et al. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor foxo1 in liver. Cell Metab. 2007; 6: 208-216
23. Frescas D, Valenti L, Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem. 2005; 280: 20589-20595
24. Banks AS, Kim-Muller JY, Mastracci TL., et al. Dissociation of the glucose and lipid regulatory functions of FoxO1 by targeted knockin of acetylation-defective alleles in mice. Cell Metab. 2011; 14: 587-597
25. Sin TK, Yung BY, Siu PM. Modulation of SIRT1-Foxo1 signaling axis by resveratrol: implications in skeletal muscle aging and insulin resistance. Cell Physiol Biochem. 2015; 35: 541-552
26. Lambert JE, Ramos-Roman MA, Browning JD., et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014; 146: 726-735
27. Taniguchi CM, Ueki K, Kahn R. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest. 2005; 115: 718-727
28. Leavens KF, Easton RM, Shulman GI., et al. Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metab. 2009; 10: 405-418
29. Ide T, Shimano H, Yahagi N., et al. SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol. 2004; 6: 351-357
30. Rametta R, Mozzi E, Dongiovanni P., et al. Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects. Int J Obes (Lond). 2013; 37: 986-992
31. Samuel VT, Choi CS, Phillips TG., et al. Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes. 2006; 55: 2042-2050
32. Peyrou M, Bourgoin L, Foti M. PTEN in non-Alcoholic fatty liver disease/non-Alcoholic steatohepatitis and cancer. Dig Dis. 2010; 28: 236-246
33. Pajvani UB, Qiang L, Kangsamaksin T., et al. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat Med. 2013; 19: 1054-1060
34. Pajvani UB, Shawber CJ, Samuel VT., et al. Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nat Med. 2011; 17: 961-967
35. Valenti L, Mendoza RM, Rametta R., et al. Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease. Diabetes. 2013; 62: 4052-4062
36. Liew PL, Wang W, Lee YC., et al. Roles of hepatic progenitor cells activation, ductular reaction proliferation and Notch signaling in morbid obesity. Hepatogastroenterology. 2012; 59: 1921-1927
37. Ferslew BC, Xie G, Johnston CK., et al. Altered bile acid metabolome in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60(11):3318-3328
38. Ma H, Patti ME. Bile acids, obesity, and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014; 28: 573-583
39. Haeusler RA, Astiarraga B, Camastra S., et al. Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids. Diabetes. 2013; 62: 4184-4191
40. Haeusler RA, Pratt-Hyatt M, Welch CL., et al. Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia. Cell Metab. 2012; 15: 65-74
41. Dongiovanni P, Petta S, Maglio C., et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015; 61: 506-514
42. Fracanzani AL, Valenti L, Bugianesi E., et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008; 48: 792-798
43. Ekstedt M, Hagstrom H, Nasr P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015; 61: 1547-1554
44. Angulo P, Kleiner DE, Dam-Larsen S., et al. Liver fibrosis, but no other histologic features, is associated with long-Term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015; 149: 389-97 e10
45. Charlton M, Sreekumar R, Rasmussen D., et al. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 2002; 35: 898-904
46. Yamaguchi K, Yang L, McCall S., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007; 45: 1366-1374
47. Fabbrini E, Mohammed BS, Magkos F., et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 2008; 134: 424-431
48. Itani SI, Ruderman NB, Schmieder F., et al. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-Alpha. Diabetes. 2002; 51: 2005-2011
49. Ussher JR, Koves TR, Cadete VJ., et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes. 2010; 59: 2453-2464
50. Ozcan U, Cao Q, Yilmaz E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004; 306: 457-461
51. Powell DJ, Hajduch E, Kular G., et al. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol Cell Biol. 2003; 23: 7794-7808
52. Samuel VT, Liu ZX, Qu X., et al. Mechanism of hepatic insulin resistance in non-Alcoholic fatty liver disease. J Biol Chem. 2004; 279: 32345-32353
53. Puri P, Mirshahi F, Cheung O., et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2008; 134: 568-576
54. Bugianesi E, Leone N, Vanni E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002; 123: 134-140
55. Valverde AM, Fabregat I, Burks DJ., et al. IRS-2 mediates the antiapoptotic effect of insulin in neonatal hepatocytes. Hepatology. 2004; 40: 1285-1294
56. Valenti L, Fracanzani AL, Dongiovanni P., et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 2002; 122: 274-280
57. Dongiovanni P, Valenti L, Rametta R., et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-Alcoholic fatty liver disease. Gut. 2010; 59: 267-273
58. Dongiovanni P, Romeo S, Valenti L. Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. Biomed Res Int. 2015; 2015: 460190
59. Dongiovanni P, Donati B, Fares R., et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol. 2013; 19: 6969-6978
60. Moschen AR, Kaser S, Tilg H. Non-Alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab. 2013; 24: 537-545
61. Valenti L, Fracanzani AL, Fargion S. The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease? Semin Immunopathol. 2009; 31: 359-369
62. Mari M, Colell A, Morales A., et al. Mechanism of mitochondrial glutathione-dependent hepatocellular susceptibility to TNF despite NF-kappaB activation. Gastroenterology. 2008; 134: 1507-1520
63. Sanyal AJ, Campbell-Sargent C, Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001; 120: 1183-1192
64. Perez-Carreras M, Del Hoyo P, Martin MA., et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003; 38: 999-1007
65. Zhang K, Shen X, Wu J., et al. Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell. 2006; 124: 587-599
66. Weiskirchen R, Tacke F. Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology. Hepatobiliary Surg Nutr. 2014; 3: 344-363
67. Pirazzi C, Valenti L, Motta BM., et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet. 2014; 23: 4077-4085
68. Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014; 20: 7381-7391
69. Paradis V, Zalinski S, Chelbi E., et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009; 49: 851-859
70. Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol. 2014; 20: 12945-12955
71. Foretz M, Guigas B, Bertrand L., et al. Metformin: from mechanisms of action to therapies. Cell Metab. 2014; 20: 953-966
72. Musso G, Cassader M, Rosina F., et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-Alcoholic fatty liver disease (NAFLD): a systematic review and meta-Analysis of randomised trials. Diabetologia. 2012; 55: 885-904
73. Uygun A, Kadayifci A, Isik AT., et al. Metformin in the treatment of patients with non-Alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004; 19 (5): 537-544
74. Bugianesi E, Gentilcore E, Manini R., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005; 100 (5): 1082-1090
75. Duseja A, Das A, Dhiman RK., et al. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol. 2007; 6 (4): 222-226
76. Haukeland JW, Konopski Z, Eggesbo HB., et al. Metformin in patients with non-Alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol. 2009; 44 (7): 853-860
77. Garinis GA, Fruci B, Mazza A., et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes. 2010; 34 (8): 1255-1264
78. Sanyal AJ, Mofrad PS, Contos MJ., et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004; 2 (12): 1107-1115
79. Belfort R, Harrison SA, Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355 (22): 2297-2307
80. Aithal GP, Thomas JA, Kaye PV., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008; 135 (4): 1176-1184
81. Idilman R, Mizrak D, Corapcioglu D., et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-Alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008; 28 (2): 200-208
82. Ratziu V, Giral P, Jacqueminet S., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008; 135 (1): 100-110
83. Omer Z, Cetinkalp S, Akyildiz M., et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2010; 22 (1): 18-23
84. Sanyal AJ, Chalasani N, Kowdley KV., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362 (18): 1675-1685
85. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000; 106: 171-176
86. Singh S, Khera R, Allen AM., et al. Comparative effectiveness of pharmacological interventions for non-Alcoholic steatohepatitis: a systematic review and network meta-Analysis. Hepatology. 2015;62(5):1417-1432
87. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab. 2012; 23: 205-215
88. Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta. 2012; 1821: 809-818
89. Neuschwander-Tetri BA, Loomba R, Sanyal AJ., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-Alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015; 385: 956-965
90. Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-Activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-Alcoholic fatty liver disease. Expert Opin Pharmacother. 2014; 15: 493-503
91. Garcia-Monzon C, Lo Iacono O, Mayoral R., et al. Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. J Hepatol. 2011; 54: 142-152
92. OShea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology. 2010; 51: 307-328
93. Hui JM, Sud A, Farrell GC., et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology. 2003; 125: 1695-1704
94. Aghemo A, Prati GM, Rumi MG., et al. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology. 2012; 56: 1681-1687
95. Banerjee S, Saito K, Ait-Goughoulte M., et al. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J Virol. 2008; 82: 2606-2612
96. Petta S, Camma C, Di Marco V., et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol. 2008; 103: 1136-1144
97. Paradis V, Perlemuter G, Bonvoust F., et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001; 34: 738-744
98. Leandro G, Mangia A, Hui J., et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-Analysis of individual patient data. Gastroenterology. 2006; 130: 1636-1642
99. Deltenre P, Louvet A, Lemoine M., et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-Analysis. J Hepatol. 2011; 55: 1187-1194
100. Overbeck K., et al. Pioglitazone in chronic hepatitis C not responding to pegylated interferon-Alpha and ribavirin. J Hepatol. 2008; 49 (2): 295-298
101. Khattab M., et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int. 2010; 30 (3): 447-454
102. Chojkier M., et al. Pioglitazone decreases hepatitis C viral load in overweight, treatment naive, genotype 4 infected-patients: a pilot study. PLoS One. 2012; 7 (3): e31516
103. Harrison SA., et al. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology. 2012; 56 (2): 464-473
104. Romero-Gomez M., et al. Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology. 2009; 50 (6): 1702-1708
105. Sharifi AH., et al. Efficacy of adding metformin to pegylated interferon and ribavirin in treatment naive patients with chronic hepatitis C: a randomized double-blind controlled trial. Middle East J Dig Dis. 2014; 6 (1): 13-17
106. Wong GL, Wong VW, Choi PC., et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2009; 58: 111-117
107. Vigano M, Valenti L, Lampertico P., et al. Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology. 2013; 58: 1245-1252
108. Carr RM, Correnti J. Insulin resistance in clinical and experimental alcoholic liver disease. Ann N Y Acad Sci. 2015;1353(1):1-20
109. Davila JA, Morgan RO, Shaib Y., et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005; 54: 533-539
110. Calle EE, Teras LR, Thun MJ. Obesity and mortality. N Engl J Med. 2005; 353: 2197-2199
111. Bhat A, Sebastiani G, Bhat M. Systematic review: preventive and therapeutic applications of metformin in liver disease. World J Hepatol. 2015; 7: 1652-1659